Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Multicenter Study

Clinical Trial, Phase II

Randomized Controlled Trial

Clinical Trial, Phase III

Review

Observational Study

Publication Year

From

Quick links

Individual year

2026

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Erb-b2 Receptor Tyrosine Kinases""[mesh_terms]

8 Results

Searching titles within these results

Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.

Tamotsu Sagawa, Hiroyuki Nagashima, Koshi Fujikawa

Medical oncology (Northwood, London, England) 2026;43(11):

Full Text

Abstract

A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer.

L Boscolo Bielo, D Trapani, P Razavi, S Chandarlapaty, Y Zhan, G Curigliano

ESMO open 2026;11(3):106064

Free Full Text

Abstract

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

Hope S Rugo, T J Pluard, P Sharma, M Melisko, G Al-Jazayrly, Y Ji, N Vidula, J Ellerton, M Smakal, M Zimovjanova, D Weng

Breast cancer research and treatment 2026;217(1):

Full Text

Abstract

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.

F Schochter, T W P Friedl, H Schäffler, F Meier-Stiegen, K N Pfister, S Riethdorf, L Wiesmüller, H Neubauer, L Müller, P Wimberger, P A Fasching, R Lorenz, T Hempel, S Heublein, A Hartkopf, K Pantel, B Rack, V Müller, T Fehm, W Janni, J P Cieslik

Breast cancer research and treatment 2026;219(3):

Full Text

Abstract

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Norikazu Masuda, Shigehira Saji, Yasuyuki Kojima, Masahiro Kitada, Hiroshi Tada, Tsutomu Iwasa, Kei Koizumi, Tsuguo Iwatani, Yasuaki Sagara, Takashi Kuwayama, Masafumi Shimoda, Tatsunari Sasada, Koichiro Tsugawa, Yoshihiro Kawaguchi, Akihiko Shimomura, Takuhiro Yamaguchi, Hiroki Hasegawa, Shun Osaka, Satoshi Morita, Toshinari Yamashita

Breast cancer research and treatment 2026;218(1):

Full Text

Abstract

Evaluation of Camptothecin Through Computational and Experimental Approaches Targeting Membrane Receptors on Breast Cancer Cells for Potential Therapeutic Applications.

Elmer Joel Millan-Casarrubias, Lucero Ruiz-Mazón, Eduardo Pérez Salazar, Pedro Cortés Reynosa, Yazmín Mariela Hernández-Rodríguez, Oscar Eduardo Cigarroa-Mayorga

International journal of molecular sciences 2026;27(17):

Full Text

Abstract

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.

Debu Tripathy, Joanne L Blum, Meghan S Karuturi, Steven McCune, Sobha Kurian, Mehdi M Moezi, Daniel M Anderson, Yan Ji, Timothy J Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z Montelongo, Zhe Zhang, Joseph C Cappelleri, Eric Gauthier, Gabrielle B Rocque

Cancer medicine 2026;15(4):e71788

Full Text

Abstract

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Elsa Campôa, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P Duhoux, Pedro Simões, Ana Rita Garcia, Vanessa Patel, Caterina Confente, Diogo Alpuim Costa, José Pereira, Catarina Santos, Marianne Paesmans, Frederico Sarmento, Teresa Gantes Padrão, Diana Simão, Daniel Bandarra, Berta Sousa, Margarida Brito, Andrea Gombos, Lieveke Ameye, Evandro de Azambuja

Breast cancer research and treatment 2026;218(1):

Full Text

Abstract

Results: 1 – 8 / 8

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Erb-b2 Receptor Tyrosine Kinases""[mesh_terms]

Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.

A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer.

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Evaluation of Camptothecin Through Computational and Experimental Approaches Targeting Membrane Receptors on Breast Cancer Cells for Potential Therapeutic Applications.

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Results for
""Erb-b2 Receptor Tyrosine Kinases""[mesh_terms]